Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2009

Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference

Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results

Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems

Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study

Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study

Peregrine Pharmaceuticals Receives Notification of Extension to Regain Compliance With NASDAQ's Minimum Bid Price Rule

Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz

Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009

Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million